Redeye initiates coverage of AddLife, a specialized European serial acquirer operating across Medtech and Labtech. Following three years of disciplined operational deleveraging the balance sheet is fully restored. Backed by resilient, non-cyclical healthcare demand and strong working capital conversion, AddLife is well positioned to step up M&A deployment and resume long-term earnings compounding.
LÄS MER
